UpdatesMarty Makary: FDA Greenlit Daraxonrasib for Pancreatic Cancer Treatment
Marty Makary: FDA Greenlit Daraxonrasib for Pancreatic Cancer Treatment
Source: Wikimedia Commons
Dr. Marty Makary, Commissioner of the U.S. Food and Drug Administration (US FDA), shared a post on social media platform, X:
TWO DAYS after receiving the application, FDA greenlit the new pancreatic cancer drug daraxonrasib for expanded access.
— Dr. Marty Makary (@DrMakaryFDA) May 1, 2026
This drug has also been granted a national priority voucher, which means a full application could be reviewed in a matter of weeks instead of 10-12 months. pic.twitter.com/zoyf3Npf4d
The US FDA had recently approved daraxonrasib for the treatment of pancreatic cancer after clinical trials showed promising results.